methyl ether of norisocamphanol | 118840-52-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: methyl ether of norisocamphanol
• 英文别名: (1S,2S,4R)-2-(methoxymethyl)bicyclo[2.2.1]heptane
• CAS: 118840-52-1；118840-53-2
• 化学式: C₉H₁₆O
• 分子量: 140.225
• InChiKey: ZDUDSOIQVVBKDR-HRDYMLBCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  氯甲基甲基醚 、 (1S,2S,4R)-bicyclo[2.2.1]heptan-2-yldiisobutylaluminum 以 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 甲基异戊基醚 、 降莰烷 、 methyl ether of norisocamphanol 、 methyl ether of norisocamphanol
  参考文献：
  名称：

  Substitution reactions with the participation of organoaluminum compounds. 7. Reaction of organoaluminum compounds with monochlorodimethyl ether

  摘要：

  DOI：

  10.1007/bf00957441

文献信息

• Adoptive Cellular Therapy Using an Agonist of Retinoic Acid Receptor-Related Orphan Receptor Gamma & Related Therapeutic Methods
  申请人：LYCERA CORPORATION

  公开号：US20170007686A1

  公开（公告）日：2017-01-12

  The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (RORγ) and provides adoptive cellular therapies using an agonist of RORγ, populations of lymphocyte cells that have been exposed to an agonist of RORγ, populations of dendritic cells that have been exposed to an agonist of RORγ, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of RORγ to a patient.
• DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20170145013A1

  公开（公告）日：2017-05-25

  The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, neurological diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.
• BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
  申请人：Lycera Corporation

  公开号：US20170190659A1

  公开（公告）日：2017-07-06

  The invention provides benzenesulfonamido and related compounds, pharmaceutical compositions, methods of promoting RORγ activity, increasing the amount of IL-17 in a subject, and treating cancer using such benzenesulfonamido and related compounds.
• TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
  申请人：Lycera Corporation

  公开号：US20170183331A1

  公开（公告）日：2017-06-29

  The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
• US9896441B2
  申请人：——

  公开号：US9896441B2

  公开（公告）日：2018-02-20